Search

Selected EMA news

November 2024New medicines recommended for approval
Eltrombopag Viatris (eltrombopag) – generic
Treatment of primary immune thrombocytopenia and thrombocytopenia associated with chronic hepatitis C (disease in which patients have low levels of blood platelets)

Alhemo (concizumab)
Prevention of bleeding in patients with hemophilia A…

Nikolai Klimko 1956-2023

Apr 26 2023 Tagged EHA-SWG Infection in Hematology, obituary, Klimko

Professor Nikolai Klimko

Professor Nikolai Klimko, MD PhD, FECMM
March 22, 1956 - March 30, 2023

With deepest sorrow we learned that on March 30, 2023, Professor Nikolai Nikolaevich Klimko passed at age 68.

First CMML guidelines produced by EHA, now available

Dec 03 2018 Posted in Press releases Tagged CMML, Guidelines, HemaSphere, European Hematology Association, European LeukemiaNet

Chronic myelomonocytic leukemia (CMML) is a rare disease with overlapping features of two categories of bone marrow and blood cell disorders that poses challenges in clinical management.

Sustainability

Actions we're taking to reduce the environmental impact of our flagship event: the EHA Congress.

Scientific networks

Specialized Working Groups (SWGs)In order to cover the full hematology field, EHA Specialized Working Groups (SWGs) are divided in two groups: disease-oriented and overarching SWGs.

Faculty Information

We are honored that you have agreed to be part of the faculty for the EHA-ISHBT Hematology Tutorial, to be held on March 1-3, 2024 in Hyderabad, India.

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

Jun 12 2015

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.